Dupilumab improves clinical outcomes in patients with asthma and perennial allergic rhinitis

Comorbid perennial allergic rhinitis (PAR), or year-round aeroallergen sensitivity, significantly contributes to disease burden in asthma patients. Dupilumab blocks the shared receptor for interleukin (IL)-4 and IL-13, key drivers of type 2 inflammation that play important roles in asthma and PAR. In LIBERTY ASTHMA QUEST (NCT02414854), dupilumab reduced severe asthma exacerbations and improved forced expiratory volume in 1 second (FEV1) in patients with uncontrolled, moderate-to-severe asthma, with greater efficacy observed in patients with elevated type 2 inflammatory biomarkers at baseline (blood eosinophils and fractional exhaled nitric oxide [FeNO]).

Source: Annals of Allergy, Asthma and Immunology - May 27, 2020 Category: Allergy & Immunology Authors: William W. Busse, Jorge F. Maspero, Yufang Lu, Jonathan Corren, Nicola A. Hanania, Bradley E. Chipps, Constance H. Katelaris, J. Mark FitzGerald, Santiago Quirce, Linda B. Ford, Megan S. Rice, Siddhesh Kamat, Asif H. Khan, Alexandre Jagerschmidt, Sivan Ha Tags: Original Article Source Type: research